Table 3.
Immunologic results after 48 weeks of TDF/FTC/EVG/cobi plus DRV.
| Week 24 | Week 48 | |
|---|---|---|
| Median CD4 count, cells/mm3 (IQR), N=21 | 500 (208.5-721) | 561 (305-698.5) |
| Patients with baseline HIV viremia (IQR), N=15 | 406 (129.5-643.2) | 565.5 (287.5-657.8) |
| Patients with baseline HIV-1 RNA <40copies/mL (IQR), N=6 | 527 (478-1036) | 400 (359-1018) |
| Median CD4 percentage (IQR), N=21 | 25 (16.5-34.5) | 26 (18.5-38.5) |
| Patients with baseline HIV viremia (IQR), N=15 | 20.5 (11.8-33.8) | 25.5 (19.2-35.5) |
| Patients with baseline HIV-1 RNA <40copies/mL (IQR), N=6 | 26 (25-41) | 32 (19-39) |
| Median change in CD4 count, cells/mm3, N=21 | +72 | +133 |
| Patients with baseline HIV viremia, N=15 | +242 | +401.5 |
| Patients with baseline HIV-1 RNA <40copies/mL, N=6 | −37 | −164 |
| Median change in CD4 percentage, N=21 | +3 | +4 |
| Patients with baseline HIV viremia, N=15 | +5.5 | +10.5 |
| Patients with baseline HIV-1 RNA <40copies/mL, N=6 | −1 | +5 |
Abbreviation: TDF/FTC/EVG/cobi plus DRV, tenofovir disoproxil fumarate, emtricitabine, and cobicistat-boosted elvitegravir plus darunavir; IQR, interquartile range.